Guarantor Financial Information (Tables)

12 Months Ended

Apr. 29, 2016

Condensed Financial Information of Parent Company Only Disclosure [Abstract]

Consolidating Statement of Comprehensive Income

Consolidating Statement of Comprehensive Income

Fiscal Year Ended April 29, 2016

Medtronic Senior Notes

(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantors			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Net sales	$	—		$	1,411		$	—		$	28,832		$	(1,410	)	$	28,833
Costs and expenses:
Cost of products sold	—			991			—			9,561			(1,410		)	9,142
Research and development expense	—			627			—			1,597			—			2,224
Selling, general, and administrative expense	10			991			—			8,468			—			9,469
Special (gains) charges, net	—			70			—			—			—			70
Restructuring charges, net	—			17			—			273			—			290
Certain litigation charges, net	—			—			—			26			—			26
Acquisition-related items	—			135			—			148			—			283
Amortization of intangible assets	—			12			—			1,919			—			1,931
Other (income) expense, net	112			(2,329		)	—			2,324			—			107
Operating profit (loss)	(122		)	897			—			4,516			—			5,291
Interest income	—			(237		)	(706		)	(448		)	960			(431		)
Interest expense	25			1,906			10			405			(960		)	1,386
Interest expense (income), net	25			1,669			(696		)	(43		)	—			955
Equity in net (income) loss of subsidiaries	(3,676		)	4,224			(2,980		)	—			2,432			—
Income (loss) from operations before income taxes	3,529			(4,996		)	3,676			4,559			(2,432		)	4,336
Provision (benefit) for income taxes	(9		)	(96		)	—			903			—			798
Net income (loss)	3,538			(4,900		)	3,676			3,656			(2,432		)	3,538
Other comprehensive income (loss), net of tax	(684		)	(493		)	(684		)	(673		)	1,850			(684		)
Total comprehensive income (loss)	$	2,854		$	(5,393	)	$	2,992		$	2,983		$	(582	)	$	2,854

Consolidating Statement of Comprehensive Income

Fiscal Year Ended April 24, 2015

Medtronic Senior Notes

(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantors			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Net sales	$	—		$	1,261		$	—		$	20,261		$	(1,261	)	$	20,261
Costs and expenses:
Cost of products sold	—			895			—			6,659			(1,245		)	6,309
Research and development expense	—			552			—			1,088			—			1,640
Selling, general, and administrative expense	1			857			—			6,046			—			6,904
Special (gains) charges	—			100			—			(138		)	—			(38		)
Restructuring charges, net	—			7			—			230			—			237
Certain litigation charges, net	—			—			—			42			—			42
Acquisition-related items	—			312			—			238			—			550
Amortization of intangible assets	—			11			—			722			—			733
Other (income) expense, net	103			(1,618		)	—			1,633			—			118
Operating profit (loss)	(104		)	145			—			3,741			(16		)	3,766
Interest income	—			(56		)	(170		)	(387		)	227			(386		)
Interest expense	—			762			—			131			(227		)	666
Interest expense (income), net	—			706			(170		)	(256		)	—			280
Equity in net (income) loss of subsidiaries	(2,790		)	(5,830		)	(2,620		)	—			11,240			—
Income (loss) from operations before income taxes	2,686			5,269			2,790			3,997			(11,256		)	3,486
Provision (benefit) for income taxes	11			(44		)	—			844			—			811
Net income	2,675			5,313			2,790			3,153			(11,256		)	2,675
Other comprehensive income (loss), net of tax	(587		)	(540		)	(587		)	(232		)	1,359			(587		)
Total comprehensive income (loss)	$	2,088		$	4,773		$	2,203		$	2,921		$	(9,897	)	$	2,088

Consolidating Statement of Comprehensive Income

Fiscal Year Ended April 25, 2014

Medtronic Senior Notes

(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantors		Subsidiary Non-guarantors			Consolidating Adjustments			Total
Net sales	$	—	$	1,155		$	—	$	17,005		$	(1,155	)	$	17,005
Costs and expenses:
Cost of products sold	—		787			—		4,674			(1,128		)	4,333
Research and development expense	—		540			—		937			—			1,477
Selling, general, and administrative expense	—		821			—		5,026			—			5,847
Special (gains) charges	—		40			—		—			—			40
Restructuring charges, net	—		71			—		7			—			78
Certain litigation charges, net	—		(24		)	—		794			—			770
Acquisition-related items	—		—			—		117			—			117
Amortization of intangible assets	—		12			—		337			—			349
Other (income) expense, net	—		(1,623		)	—		1,804			—			181
Operating profit (loss)	—		531			—		3,309			(27		)	3,813
Interest income	—		(5		)	—		(267		)	1			(271		)
Interest expense	—		317			—		63			(1		)	379
Interest expense (income), net	—		312			—		(204		)	—			108
Equity in net (income) loss of subsidiaries	—		(3,077		)	—		—			3,077			—
Income (loss) from operations before income taxes	—		3,296			—		3,513			(3,104		)	3,705
Provision (benefit) for income taxes	—		231			—		409			—			640
Net income (loss)	—		3,065			—		3,104			(3,104		)	3,065
Other comprehensive income (loss), net of tax	—		(105		)	—		(286		)	286			(105		)
Total comprehensive income (loss)	$	—	$	2,960		$	—	$	2,818		$	(2,818	)	$	2,960

Consolidating Statement of Comprehensive Income

Fiscal Year Ended April 29, 2016

CIFSA Senior Notes

(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (CIFSA)			Subsidiary Guarantors			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Net sales	$	—		$	—		$	—		$	28,833		$	—		$	28,833
Costs and expenses:
Cost of products sold	—			—			—			9,142			—			9,142
Research and development expense	—			—			—			2,224			—			2,224
Selling, general, and administrative expense	10			1			3			9,455			—			9,469
Special (gains) charges, net	—			—			—			70			—			70
Restructuring charges, net	—			—			—			290			—			290
Certain litigation charges, net	—			—			—			26			—			26
Acquisition-related items	—			—			—			283			—			283
Amortization of intangible assets	—			—			—			1,931			—			1,931
Other (income) expense, net	112			1			(18		)	12			—			107
Operating profit (loss)	(122		)	(2		)	15			5,400			—			5,291
Interest income	—			(434		)	(710		)	(451		)	1,164			(431		)
Interest expense	25			138			10			2,377			(1,164		)	1,386
Interest (income) expense, net	25			(296		)	(700		)	1,926			—			955
Equity in net (income) loss of subsidiaries	(3,676		)	(8,563		)	(2,961		)	—			15,200			—
Income (loss) from operations before income taxes	3,529			8,857			3,676			3,474			(15,200		)	4,336
Provision (benefit) for income taxes	(9		)	—			—			807			—			798
Net income (loss)	3,538			8,857			3,676			2,667			(15,200		)	3,538
Other comprehensive income (loss), net of tax	(684		)	(102		)	(684		)	(684		)	1,470			(684		)
Total comprehensive income (loss)	$	2,854		$	8,755		$	2,992		$	1,983		$	(13,730	)	$	2,854

Consolidating Statement of Comprehensive Income

Fiscal Year Ended April 24, 2015

CIFSA Senior Notes

(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (CIFSA)			Subsidiary Guarantors			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Net sales	$	—		$	—		$	—		$	20,261		$	—		$	20,261
Costs and expenses:
Cost of products sold	—			—			—			6,309			—			6,309
Research and development expense	—			—			—			1,640			—			1,640
Selling, general, and administrative expense	1			—			21			6,882			—			6,904
Special (gains) charges, net	—			—			—			(38		)	—			(38		)
Restructuring charges, net	—			—			—			237			—			237
Certain litigation charges, net	—			—			—			42			—			42
Acquisition-related items	—			—			—			550			—			550
Amortization of intangible assets	—			—			—			733			—			733
Other (income) expense, net	103			—			26			(11		)	—			118
Operating profit (loss)	(104		)	—			(47		)	3,917			—			3,766
Interest income	—			(149		)	(170		)	(386		)	319			(386		)
Interest expense	—			29			—			956			(319		)	666
Interest (income) expense, net	—			(120		)	(170		)	570			—			280
Equity in net (income) loss of subsidiaries	(2,790		)	1,412			(2,667		)	—			4,045			—
Income (loss) from operations before income taxes	2,686			(1,292		)	2,790			3,347			(4,045		)	3,486
Provision (benefit) for income taxes	11			—			—			800			—			811
Net income (loss)	2,675			(1,292		)	2,790			2,547			(4,045		)	2,675
Other comprehensive income (loss), net of tax	(587		)	200			(587		)	(587		)	974			(587		)
Total comprehensive income (loss)	$	2,088		$	(1,092	)	$	2,203		$	1,960		$	(3,071	)	$	2,088

Condensed Consolidating Balance Sheet

Condensed Consolidating Balance Sheet

April 29, 2016

Medtronic Senior Notes

(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (Medtronic, Inc.)		Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments			Total
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	55	$	—	$	2,821	$	—		$	2,876
Investments	—		—		—		9,758		—			9,758
Accounts receivable, net	—		—		—		5,562		—			5,562
Inventories	—		162		—		3,511		(200		)	3,473
Intercompany receivable	389		161,868		—		162,278		(324,535		)	—
Tax assets	—		122		—		575		—			697
Prepaid expenses and other current assets	24		149		—		1,061		—			1,234
Total current assets	413		162,356		—		185,566		(324,735		)	23,600
Property, plant and equipment, net	—		1,139		—		3,702		—			4,841
Goodwill	—		—		—		41,500		—			41,500
Other intangible assets, net	—		31		—		26,868		—			26,899
Long-term tax assets	—		690		—		693		—			1,383
Investment in subsidiaries	73,108		63,806		70,198		—		(207,112		)	—
Intercompany loans receivable	3,000		8,884		10,203		18,140		(40,227		)	—
Other assets	—		644		—		915		—			1,559
Total assets	$	76,521	$	237,550	$	80,401	$	277,384	$	(572,074	)	$	99,782
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Short-term borrowings	$	—	$	500	$	—	$	493	$	—		$	993
Accounts payable	—		288		—		1,421		—			1,709
Intercompany payable	20,486		151,687		—		152,362		(324,535		)	—
Accrued compensation	32		616		—		1,064		—			1,712
Accrued income taxes	11		—		—		555		—			566
Deferred tax liabilities	—		—		—		—		—			—
Other accrued expenses	1		243		—		1,941		—			2,185
Total current liabilities	20,530		153,334		—		157,836		(324,535		)	7,165
Long-term debt	—		26,784		—		3,463		—			30,247
Long-term accrued compensation and retirement benefits	—		1,258		—		501		—			1,759
Long-term accrued income taxes	10		1,422		—		1,471		—			2,903
Long-term intercompany loans payable	3,918		10,128		14,297		11,884		(40,227		)	—
Long-term deferred tax liabilities	—		—		—		3,729		—			3,729
Other long-term liabilities	—		202		—		1,714		—			1,916
Total liabilities	24,458		193,128		14,297		180,598		(364,762		)	47,719
Shareholders’ equity	52,063		44,422		66,104		96,786		(207,312		)	52,063
Total liabilities and shareholders’ equity	$	76,521	$	237,550	$	80,401	$	277,384	$	(572,074	)	$	99,782

Condensed Consolidating Balance Sheet

April 24, 2015

Medtronic Senior Notes

(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (Medtronic, Inc.)		Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments			Total
ASSETS
Current assets:
Cash and cash equivalents	$	263	$	1,071	$	170	$	3,339	$	—		$	4,843
Investments	—		—		—		14,637		—			14,637
Accounts receivable, net	—		—		—		5,112		—			5,112
Inventories	—		165		—		3,497		(199		)	3,463
Intercompany receivable	259		146,942		—		144,638		(291,839		)	—
Tax assets	—		295		—		1,040		—			1,335
Prepaid expenses and other current assets	4		128		—		1,322		—			1,454
Total current assets	526		148,601		170		173,585		(292,038		)	30,844
Property, plant and equipment, net	—		976		—		3,723		—			4,699
Goodwill	—		—		—		40,530		—			40,530
Other intangible assets, net	—		39		—		28,062		—			28,101
Long-term tax assets	—		294		—		480		—			774
Investment in subsidiaries	70,233		68,710		63,063		—		(202,006		)	—
Intercompany loans receivable	3,000		6,516		10,000		10,218		(29,734		)	—
Other assets	—		678		—		1,059		—			1,737
Total assets	$	73,759	$	225,814	$	73,233	$	257,657	$	(523,778	)	$	106,685
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Short-term borrowings	$	—	$	1,110	$	—	$	1,324	$	—		$	2,434
Accounts payable	—		261		—		1,349		—			1,610
Intercompany payable	20,506		135,660		—		135,673		(291,839		)	—
Accrued compensation	1		490		—		1,120		—			1,611
Accrued income taxes	19		—		—		916		—			935
Deferred tax liabilities	3		—		—		116		—			119
Other accrued expenses	—		628		—		1,836		—			2,464
Total current liabilities	20,529		138,149		—		142,334		(291,839		)	9,173
Long-term debt	—		29,004		—		4,748		—			33,752
Long-term accrued compensation and retirement benefits	—		965		—		570		—			1,535
Long-term accrued income taxes	—		1,048		—		1,428		—			2,476
Long-term intercompany loans payable	—		10,218		10,000		9,516		(29,734		)	—
Long-term deferred tax liabilities	—		—		—		4,700		—			4,700
Other long-term liabilities	—		207		—		1,612		—			1,819
Total liabilities	20,529		179,591		10,000		164,908		(321,573		)	53,455
Shareholders’ equity	53,230		46,223		63,233		92,749		(202,205		)	53,230
Total liabilities and shareholders’ equity	$	73,759	$	225,814	$	73,233	$	257,657	$	(523,778	)	$	106,685

Condensed Consolidating Balance Sheet

April 29, 2016

CIFSA Senior Notes

(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (CIFSA)		Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments			Total
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	208	$	—	$	2,668	$	—		$	2,876
Investments	—		—		—		9,758		—			9,758
Accounts receivable, net	—		—		—		5,562		—			5,562
Inventories	—		—		—		3,473		—			3,473
Intercompany receivable	389		—		61		20,469		(20,919		)	—
Tax assets	—		—		—		697		—			697
Prepaid expenses and other current assets	24		—		—		1,210		—			1,234
Total current assets	413		208		61		43,837		(20,919		)	23,600
Property, plant and equipment, net	—		—		1		4,840		—			4,841
Goodwill	—		—		—		41,500		—			41,500
Other intangible assets, net	—		—		—		26,899		—			26,899
Long-term tax assets	—		—		—		1,383		—			1,383
Investment in subsidiaries	73,108		41,582		68,875		—		(183,565		)	—
Intercompany loans receivable	3,000		8,253		11,465		27,724		(50,442		)	—
Other assets	—		—		—		1,559		—			1,559
Total assets	$	76,521	$	50,043	$	80,402	$	147,742	$	(254,926	)	$	99,782
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Short-term borrowings	$	—	$	—	$	—	$	993	$	—		$	993
Accounts payable	—		—		—		1,709		—			1,709
Intercompany payable	20,486		—		—		433		(20,919		)	—
Accrued compensation	32		—		—		1,680		—			1,712
Accrued income taxes	11		—		—		555		—			566
Deferred tax liabilities	—		—		—		—		—			—
Other accrued expenses	1		24		—		2,160		—			2,185
Total current liabilities	20,530		24		—		7,530		(20,919		)	7,165
Long-term debt	—		3,382		—		26,865		—			30,247
Long-term accrued compensation and retirement benefits	—		—		—		1,759		—			1,759
Long-term accrued income taxes	10		—		—		2,893		—			2,903
Long-term intercompany loans payable	3,918		14,689		14,298		17,537		(50,442		)	—
Long-term deferred tax liabilities	—		—		—		3,729		—			3,729
Other long-term liabilities	—		—		—		1,916		—			1,916
Total liabilities	24,458		18,095		14,298		62,229		(71,361		)	47,719
Shareholders’ equity	52,063		31,948		66,104		85,513		(183,565		)	52,063
Total liabilities and shareholders’ equity	$	76,521	$	50,043	$	80,402	$	147,742	$	(254,926	)	$	99,782

Condensed Consolidating Balance Sheet

April 24, 2015

CIFSA Senior Notes

(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (CIFSA)		Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments			Total
ASSETS
Current assets:
Cash and cash equivalents	$	263	$	728	$	170	$	3,682	$	—		$	4,843
Investments	—		—		—		14,637		—			14,637
Accounts receivable, net	—		—		—		5,112		—			5,112
Inventories	—		—		—		3,463		—			3,463
Intercompany receivable	259		—		269		20,506		(21,034		)	—
Tax assets	—		—		—		1,335		—			1,335
Prepaid expenses and other current assets	4		—		6		1,444		—			1,454
Total current assets	526		728		445		50,179		(21,034		)	30,844
Property, plant and equipment, net	—		—		1		4,698		—			4,699
Goodwill	—		—		—		40,530		—			40,530
Other intangible assets, net	—		—		—		28,101		—			28,101
Long-term tax assets	—		—		—		774		—			774
Investment in subsidiaries	70,233		28,663		61,768		—		(160,664		)	—
Intercompany loans receivable	3,000		7,401		11,303		17,082		(38,786		)	—
Other assets	—		—		—		1,737		—			1,737
Total assets	$	73,759	$	36,792	$	73,517	$	143,101	$	(220,484	)	$	106,685
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Short-term borrowings	$	—	$	1,002	$	—	$	1,432	$	—		$	2,434
Accounts payable	—		—		2		1,608		—			1,610
Intercompany payable	20,506		—		279		249		(21,034		)	—
Accrued compensation	1		—		—		1,610		—			1,611
Accrued income taxes	19		—		—		916		—			935
Deferred tax liabilities	3		—		—		116		—			119
Other accrued expenses	—		40		1		2,423		—			2,464
Total current liabilities	20,529		1,042		282		8,354		(21,034		)	9,173
Long-term debt	—		4,581		—		29,171		—			33,752
Long-term accrued compensation and retirement benefits	—		—		—		1,535		—			1,535
Long-term accrued income taxes	—		—		—		2,476		—			2,476
Long-term intercompany loans payable	—		8,385		10,002		20,399		(38,786		)	—
Long-term deferred tax liabilities	—		—		—		4,700		—			4,700
Other long-term liabilities	—		—		—		1,819		—			1,819
Total liabilities	20,529		14,008		10,284		68,454		(59,820		)	53,455
Shareholders’ equity	53,230		22,784		63,233		74,647		(160,664		)	53,230
Total liabilities and shareholders’ equity	$	73,759	$	36,792	$	73,517	$	143,101	$	(220,484	)	$	106,685

Condensed Consolidating Statement of Cash Flows

Condensed Consolidating Statement of Cash Flows

Fiscal Year Ended April 29, 2016

Medtronic Senior Notes

(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantors			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Operating Activities:
Net cash provided by (used in) operating activities	$	297		$	402		$	696		$	4,635		$	(812	)	$	5,218
Investing Activities:
Acquisitions, net of cash acquired	—			(526		)	—			(687		)	—			(1,213		)
Additions to property, plant, and equipment	—			(334		)	—			(712		)	—			(1,046		)
Purchases of marketable securities	—			—			—			(5,406		)	—			(5,406		)
Sales and maturities of marketable securities	—			—			—			9,924			—			9,924
Net (increase) decrease in intercompany loans receivable	—			(2,368		)	(203		)	(7,921		)	10,492			—
Capital contributions paid	—			(11		)	(4,959		)	(4,900		)	9,870			—
Other investing activities, net	—			—			—			(14		)	—			(14		)
Net cash provided by (used in) investing activities	—			(3,239		)	(5,162		)	(9,716		)	20,362			2,245
Financing Activities:
Acquisition-related contingent consideration	—			—			—			(22		)	—			(22		)
Change in short-term borrowings, net	—			—			—			7			—			7
Repayment of short-term borrowings (maturities greater than 90 days)	—			—			(139		)	—			—			(139		)
Proceeds from short-term borrowings (maturities greater than 90 days)	—			—			139			—			—			139
Issuance of long-term debt	—			—			—			—			—			—
Payments on long-term debt	—			(2,988		)	—			(2,144		)	—			(5,132		)
Dividends to shareholders	(2,139		)	—			—			—			—			(2,139		)
Issuance of ordinary shares	491			—			—			—			—			491
Repurchase of ordinary shares	(2,830		)	—			—			—			—			(2,830		)
Net intercompany loan borrowings (repayments)	3,918			(91		)	4,296			2,369			(10,492		)	—
Intercompany dividend paid	—			—			—			(812		)	812			—
Capital contributions received	—			4,900			—			4,970			(9,870		)	—
Other financing activities	—			—			—			82			—			82
Net cash provided by (used in) financing activities	(560		)	1,821			4,296			4,450			(19,550		)	(9,543		)
Effect of exchange rate changes on cash and cash equivalents	—			—			—			113			—			113
Net change in cash and cash equivalents	(263		)	(1,016		)	(170		)	(518		)	—			(1,967		)
Cash and cash equivalents at beginning of period	263			1,071			170			3,339			—			4,843
Cash and cash equivalents at end of period	$	—		$	55		$	—		$	2,821		$	—		$	2,876

Condensed Consolidating Statement of Cash Flows

Fiscal Year Ended April 24, 2015

Medtronic Senior Notes

(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantors		Subsidiary Non-guarantors			Consolidating Adjustments			Total
Operating Activities:
Net cash provided by (used in) operating activities	$	26		$	1,479		$	170	$	3,640		$	(413	)	$	4,902
Investing Activities:
Acquisitions, net of cash acquired	(9,700		)	(65		)	—		(5,119		)	—			(14,884		)
Additions to property, plant, and equipment	—			(187		)	—		(384		)	—			(571		)
Purchases of marketable securities	—			—			—		(7,582		)	—			(7,582		)
Sales and maturities of marketable securities	—			—			—		5,890			—			5,890
Net (increase) decrease in intercompany loans receivable	—			(16,996		)	—		53			16,943			—
Other investing activities, net	—			—			—		89			—			89
Net cash provided by (used in) investing activities	(9,700		)	(17,248		)	—		(7,053		)	16,943			(17,058		)
Financing Activities:
Acquisition-related contingent consideration	—			—			—		(85		)	—			(85		)
Change in short-term borrowings, net	—			—			—		(1		)	—			(1		)
Repayment of short-term borrowings (maturities greater than 90 days)	—			(150		)	—		—			—			(150		)
Proceeds from short-term borrowings (maturities greater than 90 days)	—			150			—		—			—			150
Issuance of long-term debt	—			19,942			—		—			—			19,942
Payments on long-term debt	—			(1,268		)	—		—			—			(1,268		)
Dividends to shareholders	(435		)	(902		)	—		—			—			(1,337		)
Issuance of ordinary shares	172			477			—		—			—			649
Repurchase of ordinary shares	(300		)	(1,620		)	—		—			—			(1,920		)
Net intercompany loan borrowings (repayments)	10,500			(53		)	—		6,496			(16,943		)	—
Intercompany dividends paid	—			—			—		(413		)	413			—
Other financing activities	—			—			—		(31		)	—			(31		)
Net cash provided by (used in) financing activities	9,937			16,576			—		5,966			(16,530		)	15,949
Effect of exchange rate changes on cash and cash equivalents	—			—			—		(353		)	—			(353		)
Net change in cash and cash equivalents	263			807			170		2,200			—			3,440
Cash and cash equivalents at beginning of period	—			264			—		1,139			—			1,403
Cash and cash equivalents at end of period	$	263		$	1,071		$	170	$	3,339		$	—		$	4,843

Condensed Consolidating Statement of Cash Flows

Fiscal Year Ended April 25, 2014

Medtronic Senior Notes

(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantors		Subsidiary Non-guarantors			Consolidating Adjustments			Total
Operating Activities:
Net cash provided by (used in) operating activities	$	—	$	1,384		$	—	$	3,949		$	(374	)	$	4,959
Investing Activities:
Acquisitions, net of cash acquired	—		—			—		(385		)	—			(385		)
Additions to property, plant, and equipment	—		(154		)	—		(242		)	—			(396		)
Purchases of marketable securities	—		—			—		(10,895		)	—			(10,895		)
Sales and maturities of marketable securities	—		—			—		8,111			—			8,111
Net (increase) decrease in intercompany loans receivable	—		1			—		(12		)	11			—
Other investing activities, net	—		—			—		(29		)	—			(29		)
Net cash provided by (used in) investing activities	—		(153		)	—		(3,452		)	11			(3,594		)
Financing Activities:
Acquisition-related contingent consideration	—		—			—		(1		)	—			(1		)
Change in short-term borrowings, net	—		—			—		127			—			127
Repayment of short-term borrowings (maturities greater than 90 days)	—		(1,301		)	—		—			—			(1,301		)
Proceeds from short-term borrowings (maturities greater than 90 days)	—		1,045			—		131			—			1,176
Issuance of long-term debt	—		1,994			—		—			—			1,994
Payments on long-term debt	—		(565		)	—		—			—			(565		)
Dividends to shareholders	—		(1,116		)	—		—			—			(1,116		)
Issuance of ordinary shares	—		1,307			—		—			—			1,307
Repurchase of ordinary shares	—		(2,553		)	—		—			—			(2,553		)
Net intercompany loan borrowings (repayments)	—		12			—		(1		)	(11		)	—
Intercompany dividends paid	—		—			—		(374		)	374			—
Other financing activities	—		14			—		—			—			14
Net cash provided by (used in) financing activities	—		(1,163		)	—		(118		)	363			(918		)
Effect of exchange rate changes on cash and cash equivalents	—		—			—		37			—			37
Net change in cash and cash equivalents	—		68			—		416			—			484
Cash and cash equivalents at beginning of period	—		196			—		723			—			919
Cash and cash equivalents at end of period	$	—	$	264		$	—	$	1,139		$	—		$	1,403

Condensed Consolidating Statement of Cash Flows

Fiscal Year Ended April 29, 2016

CIFSA Senior Notes

(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (CIFSA)			Subsidiary Guarantors			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Operating Activities:
Net cash provided by (used in) operating activities	$	297		$	4,208		$	604		$	4,114		$	(4,005	)	$	5,218
Investing Activities:
Acquisitions, net of cash acquired	—			—			—			(1,266		)	53			(1,213		)
Additions to property, plant, and equipment	—			—			—			(1,046		)	—			(1,046		)
Purchases of marketable securities	—			—			—			(5,406		)	—			(5,406		)
Sales and maturities of marketable securities	—			—			—			9,924			—			9,924
Net (increase) decrease in intercompany loans receivable	—			(8,193		)	(164		)	(3,302		)	11,659			—
Sales of subsidiaries	—			—			53			—			(53		)	—
Capital contributions paid	—			(720		)	(4,959		)	—			5,679			—
Other investing activities, net	—			—			—			(14		)	—			(14		)
Net cash provided by (used in) investing activities	—			(8,913		)	(5,070		)	(1,110		)	17,338			2,245
Financing Activities:
Acquisition-related contingent consideration	—			—			—			(22		)	—			(22		)
Change in short-term borrowings, net	—			—			—			7			—			7
Repayment of short-term borrowings (maturities greater than 90 days)	—			—			(139		)	—			—			(139		)
Proceeds from short-term borrowings (maturities greater than 90 days)	—			—			139			—			—			139
Issuance of long-term debt	—			—			—			—			—			—
Payments on long-term debt	—			(2,121		)	—			(3,011		)	—			(5,132		)
Dividends to shareholders	(2,139		)	—			—			—			—			(2,139		)
Issuance of ordinary shares	491			—			—			—			—			491
Repurchase of ordinary shares	(2,830		)	—			—			—			—			(2,830		)
Net intercompany loan borrowings (repayments)	3,918			6,306			4,296			(2,861		)	(11,659		)	—
Intercompany dividend paid	—			—			—			(4,005		)	4,005			—
Capital Contributions received	—			—			—			5,679			(5,679		)	—
Other financing activities	—			—			—			82			—			82
Net cash provided by (used in) financing activities	(560		)	4,185			4,296			(4,131		)	(13,333		)	(9,543		)
Effect of exchange rate changes on cash and cash equivalents	—			—			—			113			—			113
Net change in cash and cash equivalents	(263		)	(520		)	(170		)	(1,014		)	—			(1,967		)
Cash and cash equivalents at beginning of period	263			728			170			3,682			—			4,843
Cash and cash equivalents at end of period	$	—		$	208		$	—		$	2,668		$	—		$	2,876

Condensed Consolidating Statement of Cash Flows

Fiscal Year Ended April 24, 2015

CIFSA Senior Notes

(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (CIFSA)			Subsidiary Guarantors			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Operating Activities:
Net cash provided by (used in) operating activities	$	26		$	1,238		$	142		$	4,596		$	(1,100	)	$	4,902
Investing Activities:
Acquisitions, net of cash acquired	(9,700		)	440			—			(5,624		)	—			(14,884		)
Additions to property, plant, and equipment	—			—			(1		)	(570		)	—			(571		)
Purchases of marketable securities	—			—			—			(7,582		)	—			(7,582		)
Sales and maturities of marketable securities	—			—			—			5,890			—			5,890
Net (increase) decrease in intercompany loans receivable	—			(59		)	29			(10,626		)	10,656			—
Capital contributions paid	—			(937		)	—			—			937			—
Other investing activities, net	—			—			—			89			—			89
Net cash provided by (used in) investing activities	(9,700		)	(556		)	28			(18,423		)	11,593			(17,058		)
Financing Activities:
Acquisition-related contingent consideration	—			—			—			(85		)	—			(85		)
Change in short-term borrowings, net	—			—			—			(1		)	—			(1		)
Repayment of short-term borrowings (maturities greater than 90 days)	—			—			(150		)	—			—			(150		)
Proceeds from short-term borrowings (maturities greater than 90 days)	—			—			150			—			—			150
Issuance of long-term debt	—			—			—			19,942			—			19,942
Payments on long-term debt	—			(51		)	—			(1,217		)	—			(1,268		)
Dividends to shareholders	(435		)	—			—			(902		)	—			(1,337		)
Issuance of ordinary shares	172			—			—			477			—			649
Repurchase of ordinary shares	(300		)	—			—			(1,620		)	—			(1,920		)
Net intercompany loan borrowings (repayments)	10,500			97			—			59			(10,656		)	—
Intercompany dividend paid	—			—			—			(1,100		)	1,100			—
Capital contributions received	—			—			—			937			(937		)	—
Other financing activities	—			—			—			(31		)	—			(31		)
Net cash provided by (used in) financing activities	9,937			46			—			16,459			(10,493		)	15,949
Effect of exchange rate changes on cash and cash equivalents	—			—			—			(353		)	—			(353		)
Net change in cash and cash equivalents	263			728			170			2,279			—			3,440
Cash and cash equivalents at beginning of period	—			—			—			1,403			—			1,403
Cash and cash equivalents at end of period	$	263		$	728		$	170		$	3,682		$	—		$	4,843